IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


(Investigative Ophthalmology and Visual Science. 2007;48:2967-2974.)
© 2007 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.06-1522

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Movie
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Folberg, R.
Right arrow Articles by Maniotis, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Folberg, R.
Right arrow Articles by Maniotis, A. J.

Modeling the Behavior of Uveal Melanoma in the Liver

Robert Folberg,1 Lu Leach,1 Klara Valyi-Nagy,1 Amy Y. Lin,1 Marsha A. Apushkin,1 Zhuming Ai,2 Vivian Barak,3 Dibyen Majumdar,4 Jacob Pe’er,5 and Andrew J. Maniotis1

1From the Department of Pathology, the 2Virtual Reality in Medicine Laboratory, Department of Biomedical and Health Information Sciences, and the 4Department of Mathematics, Statistics, and Computer Science, University of Illinois at Chicago, Chicago, Illinois; and the 3Immunology Laboratory for Tumor Diagnosis and the 5Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

PURPOSE. To model the behavior of uveal melanoma in the liver.

METHODS. A 15-µL suspension of metastatic MUM2B or either primary OCM1 or M619 uveal melanoma cells was injected into the liver parenchyma of 105 CB17 SCID mice through a 1-cm abdominal incision. Animals were killed at 2, 4, 6, or 8 weeks after injection. Before euthanatization, 3% FITC-BSA buffer was injected into the retro-orbital plexus of one eye of three mice. Liver tissues were examined by light and fluorescence microscopy, and were stained with human anti-laminin. Vasculogenic mimicry patterns were reconstructed from serial laser scanning confocal microscopic stacks.

RESULTS. OCM1a cells formed microscopic nodules in the mouse liver within 2 weeks after injection and metastasized to the lung 6 weeks later. By contrast, M619 and MUM2B cells formed expansile nodules in the liver within 2 weeks and gave rise to pulmonary metastases within 4 weeks after injection. Vasculogenic mimicry patterns, composed of human laminin and identical with those in human primary and metastatic uveal melanomas, were detected in the animal model. The detection of human rather than mouse laminin in the vasculogenic mimicry patterns in this model demonstrates that these patterns were of tumor cell origin and were not co-opted from the mouse liver microenvironment.

CONCLUSIONS. There are currently no effective treatments for metastatic uveal melanoma. This direct-injection model focuses on critical interactions between the tumor cell and the liver. It provides for translationally relevant approaches to the development of new modalities to detect small tumor burdens in patients, to study the biology of clinical dormancy of metastatic disease in uveal melanoma, to design and test novel treatments to prevent the emergence of clinically manifest liver metastases after dormancy, and to treat established uveal melanoma metastases.





This article has been cited by other articles:


Home page
IOVSHome page
V. Barak, S. Frenkel, K. Valyi-Nagy, L. Leach, M. A. Apushkin, A. Y. Lin, I. Kalickman, N. A. Baumann, J. Pe'er, A. J. Maniotis, et al.
Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4399 - 4402.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Association for Research in Vision and Ophthalmology